MicroRNAs in the early diagnosis of pancreatic cancer / 中国生化药物杂志

ABSTRACT

Objective To analyze the clinical value of microRNAs applied in the early diagnosis of pancreatic cancer.Methods The expression of mir-155,mir-196a,mir-181a,mir-181b in three pancreatic cancer cell lines PANC-1,PaCa-2,AsPC-1 pancreatic cancer,normal pancreatic cells and plasmas of 100 patients with pancreatic cancer ,100 normal volunteers were detected by Real-time PCR,and the results were analyzed.The expression of mir-155,mir-196a,mir-181a,mir-181b in 100 pancreatic cancer tissues and 100 normal pancreatic tissues were detected by immunohistochemical,and the results were analyzed. Results Real-timePCR test results showed that compared with normal pancreatic cells,mir-155,mir-196a expression in three pancreatic cancer cells PANC-1,PaCa-2,AsPC-1 were significantly increased(P<0.05).Compared with healthy volunteers,mir-155,mir-196a,mir-181a,mir-181b expression of plasma in pancreatic cancer patients were significantly higher(P<0.05).Immunohistochemistry results showed that mir-155,mir-196a mir-181a and mir-181b expression in pancreatic tissue were significantly higher than that in normal pancreatic tissue (P <0.05 ).Conclusion The expression of mir-155,mir-196a,mir-181a and mir-181b are high in pancreatic cancer tissues and pancreatic cancer cell lines,which are closely related to the development of pancreatic cancer.Those microRNAs are expected to be cancer markers for early diagnosis of,pancreatic cancer,have highly diagnostic value and broad clinical application.